Results 51 to 60 of about 61,613 (221)

Effect of echinacoside as a palliative for irinotecan-induced intestinal mucositis

Интегративная физиология, 2023
Irinotecan, an anticancer drug, causes severe delayed diarrhea due to its active metabolite, SN-38, which damages the intestinal mucosa. This diarrhea may lead to the discontinuation of anticancer therapy in clinical practice.
Хикару Оцуки, Шизука Джонан, Тайсэй Цудзии, Нахла Хамуда, Кикуко Амагазе   +4 more
doaj   +1 more source

Impact of omega 3 alone or in combination with irinotecan on bone marrow and spleen of rats: in vivo study

Iraqi Journal of Pharmaceutical Sciences, 2023
Objectives: The present study designed to explore the genotoxicity through measurement of Mitotic index in bone marrow and the spleen cells, as possible mechanism of bone marrow and spleen toxicity that induced by irinotecan; and to describe the ...
Alaa Radhi, Nada Al-Shawi, Ali Hassan
doaj   +1 more source

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Therapeutic Advances in Medical Oncology, 2020
Background: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. Methods: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or ...
Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Genichiro Ishii, Kohei Shitara   +14 more
doaj   +1 more source

Lorlatinib‐Containing Therapy for MYCN‐Amplified, ALK‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim, Minji Kim, Nani Jung, Sung Eun Kim, Ji Yoon Kim, Mi Ae Chu, Jung Eun Kwon, Yeo Hyang Kim, So Mi Lee, Ki‐Su Park, Jeong Eun Lee, Ye Jee Shim   +11 more
wiley   +1 more source

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses [PDF]

, 2012
Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Hartley, J.A., MacPherson, I.R.J., Masanori Miwa, Hartley, JM, Jones, K, Crawford Donna, Saito Tomohisa, Evans, TRJ, Hartley, JA, Jones Keith, MacPherson, IRJ, Abe Masaichi, Crawford, D, Jones, K., D Alan Anthoney, John M Hartley, Saito, T., Twelves, C., Hartley Janet A, Anthoney, D.A., Christopher Twelves, Anthoney, DA, Miwa, M., Miwa Masanori, TRJ Evans, Evans, T.R.J., Naik, J, Jay Naik, Donna Crawford, Keith Jones, Abe, M., Saito, T, Tomohisa Saito, Abe, M, Naik Jay, Naik, J., MacPherson Iain RJ, Evans TRJ, Hartley, J.M., Hartley John M, Masaichi Abe, Miwa, M, Twelves, C, Crawford, D., Anthoney D, Janet A Hartley, Twelves Christopher, Iain RJ MacPherson   +47 more
core   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Plant Metabolites Screening Identifies 7‐epi‐10‐Deacetyltaxol Inhibiting Cell Division by Interfering With the Cell Cycle and Microtubule Organization

Advanced Science, EarlyView.
In this study, an efficient screening system is developed for plant metabolites to find a compound, 7‐epi‐10‐deacetyltaxol, inhibits tissue elongation. It suppresses plant growth through brassinosteroid and microtubule pathways. It is later applied to animal cells and human tumor organoids, resulting in similar cell division suppression. These findings
Yan‐Jie Zhang, Yu‐Xuan Bai, Geng G. Tian, Bin Zhang, Ding‐Yi Lu, Qing‐Ping Yao, Wen‐Hao Tian, Xiao‐Na Wei, Jing‐Ting Yang, Ze‐Yu Xiong, Yi Lu, Yu‐Tong Jiang, Chun‐Hui Cai, Yu‐Ming Lu, Xian‐Qing Jia, Li‐Li Jing, Bao‐Jun Yang, Ying‐Xin Qi, Xin‐Xin Han, Ji Wu, Wen‐Hui Lin   +20 more
wiley   +1 more source

A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage
Treatment in Refractory or Relapsed Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2013
Background and objective At present no standard second-line combination has been established for recurrent small cell lung cancer (SCLC). Therefore we evaluate the efficacy and safety of irinotecan in combination with nedaplatin/cisplatin against ...
Shufei YU, Yan WANG, Xingsheng HU, Hongyu WANG, Xuezhi HAO, Jianping XU, Junling LI, Xiangru ZHANG, Yuankai SHI   +8 more
doaj   +1 more source

Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting

Advanced Science, EarlyView.
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang, Lu Chen, Jia Qin, Xiaoning Wang, Sunlan Ye, Ning An, Mei Bai, Yan Shen, Xuefeng Wu, Qiang Xu   +9 more
wiley   +1 more source